BioCentury
ARTICLE | Company News

Calypso, EA Pharma deal

April 7, 2017 4:22 AM UTC

Calypso granted EA Pharma exclusive, worldwide rights to develop and commercialize preclinical candidate CALY-001. The companies will collaborate to develop the human mAb targeting matrix metalloproteinase 9 (MMP9) to treat inflammatory bowel disease (IBD). ...